Trials / Unknown
UnknownNCT05434585
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO-CoV.617.2) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1 study to evaluate safety, tolerability, and immunogenicity of SARS-CoV-2 variant mRNA vaccines which are used to prevent COVID-19 caused by SARS-CoV-2 infection. this study is conducted during Indonesian subjects aged 18 years and older who have not received SARS-CoV-2 vaccines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ABO1009-DP | Vaccine |
| BIOLOGICAL | ABO-CoV.617.2 | Vaccine |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2022-07-08
- Primary completion
- 2022-10-10
- Completion
- 2023-08-30
- First posted
- 2022-06-28
- Last updated
- 2023-02-08
Locations
2 sites across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT05434585. Inclusion in this directory is not an endorsement.